A combined biomarker assay may predict which AAV patients will not respond to RTX therapy A next step towards precision / personalized rheumatology? @RheumNow #ACR25 Abst 1602 https://t.co/gcrZUNV0b9

Safety & benefit of #Deucravacitinib in #SLE #LTE #PAISLEY #RCT 👇 over 4 yrs Stable response sustained over 4 yrs No new Safety signals Await Ph3 RCT results - fully enrolled #SoTyktu Abst#LB10 #ACR25 @RheumNow @ACRheum https://t.co/ZpmzOYVnq9

#1263 More from our health literacy work! @KingsCollegeNHS, 11 distinct health literacy profiles were identified from 263 rheum patients. Lower literacy linked to unemployment & non-White ethnicity, highlighting equity gaps in care & need for improved resources @RheumNow #ACR25 https://t.co/QxzMFLykyE

#1639 In 2 lupus cohorts (n=619), 1 in 4 had mismatch between self-reported & measured physical function. Higher BMI, disease activity & depression linked to underreporting ability ➡️ self-report ≠ performance! Important for SLE care & research. @RheumNow #ACR25 https://t.co/kMlChreJPh

Avouac et al. Lipid changes after JAKi initiation. 85 patients. Increases at 6 months. Largely appeared driven by HDL increase, and correlated CRP decrease. Appeared transient with return to baseline with time. @RheumNow #ACR25 Abstr#1333 https://t.co/CQ6u3ck1Ch

GLP1 receptors are present on cartilage, synovial and specific cells such as macrophages. Also endogenous GLP1 seemed to protect the cartilage in animal models #ACR25 @RheumNow https://t.co/ekNWbtPO4b

Ultra-low dose (ULD) RTX in AAV maintenance 200mg q6 mo vs. 500mg q6 mo interim analysis No major difference in infection risk or hypogammaglobulinemia thus far but both doses appeared similarly efficacious #ACR25 @rheumnow Abst 1609 https://t.co/ZGYNVGY3dr

The axSpA Registry of Ireland (ASRI): 10% reported depression, w/ higher prev in older cohorts. Pts w/ depression had ⬆️peripheral involvement, ⬆️dse activity & poor functional status 💡Consider the impact of non-inflamm factors in dse burden #ACR25 @RheumNow Abs1409 https://t.co/yDfHA24M6e

Icotrokinra, the new kid on the bloc! Targeted oral peptide IL-23R-inhibitor Effective in Ph2 and Ph3 in PSO Adults Data in Adolescents (12-18yo) with PSO ICO 200mg QD 44pts vs. PBO 22pts 16wks All pts received ICO wk16-wk24 Clear/Almost clear skin IGA 0/1 84% vs. 24% PASI 90 https://t.co/77YvXtdLi1

@RheumNow on Social Media: ✧ virtual learning is the future of medicine ✧use digital strategies to filter good data online- AI can help focus interests & stay up to date - ex. Consensus or Feedly! ✧ peer to peer learning through social media enhances learning #ACR25 https://t.co/n6MzhYoz0n